Prostate Cancer | Specialty

FDA Approved Agents for Non-Metastatic CRPC

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

July 9th 2020

Neoadjuvant Apalutamide May Shrink Prostate Tumors

July 8th 2020

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Dr. Hope on the Effectiveness of 68Ga-PSMA-11 PET in Prostate Cancer

July 8th 2020

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Dr. Shore on the Potential Utility of Relugolix in Advanced Prostate Cancer

July 8th 2020

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Dr. Hope on the Impact of Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

July 6th 2020

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Early Biomarker Data Provide Framework for Precision Medicine-Based Trials in Prostate Cancer

July 2nd 2020

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.

Dr. Shore on the Safety Profiles of Relugolix and Leuprolide in Prostate Cancer

July 1st 2020

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Pivotal Phase 3 CONTACT-02 Trial of Cabozantinib/Atezolizumab in mCRPC Initiated

June 30th 2020

Exelixis, Inc. has launched the phase 3 CONTACT-02 trial examining cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer who have received prior treatment with 1 novel hormonal therapy.

Dr. Rana on the Prevalence of Pathogenic Variants in Prostate Cancer

June 30th 2020

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Atezolizumab/Radium-223 Combo Shows No Benefit in mCRPC, But Biomarker Work Planned

June 29th 2020

Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Systematic Germline Genetic Testing Is Feasible in Veterans With Metastatic Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Dr. Saad on Unanswered Questions From the SPARTAN Trial in M0CRPC

June 29th 2020

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Dr. Sokolova on the Rationale for Systematic Germline Testing in Prostate Cancer

June 29th 2020

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

June 29th 2020

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

NICE Passes on Abiraterone for Newly Diagnosed, High-Risk Metastatic Hormone-Sensitive Prostate Cancer

June 26th 2020

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend abiraterone acetate with prednisone/prednisolone plus androgen deprivation therapy as a treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate cancer.

Dr. Chi on the Utility of Liquid Biopsy in Prostate Cancer

June 26th 2020

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.